The U.S. Trade Representative's office is reviewing the Indian Supreme Court's drug patent ruling. The agency could address the verdict in its yearly report on intellectual property rights protections, which is expected this month. India has previously been on the report's "priority watch list." "This decision marks yet another example of the deteriorating innovation environment in India," PhRMA CEO John J. Castellani said.

Full Story:

Related Summaries